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Background and Aims. Nonalcoholic fatty liver disease is
epidemiologically associatedwithhepatic andmeta-
bolic disorders. Theaimof this studywas to examine
whether hepatic fat accumulation has a causal role
in determining liver damage and insulin resistance.
Methods. We performed a Mendelian randomization
analysis using risk alleles in PNPLA3, TM6SF2,
GCKR and MBOAT7, and a polygenic risk score for
hepatic fat, as instruments. We evaluated comple-
mentary cohorts of at-risk individuals and individ-
uals from the general population: 1515 from the
liver biopsy cohort (LBC), 3329 from the Swedish
Obese Subjects Study (SOS) and 4570 from the
population-based Dallas Heart Study (DHS).
Results. Hepatic fat was epidemiologically associated
with liver damage, insulin resistance, dyslipidemia
and hypertension. The impact of genetic variants
on liver damage was proportional to their effect on
hepatic fat accumulation. Genetically determined
hepatic fat was associated with aminotransferases,
and with inflammation, ballooning and fibrosis in
the LBC. Furthermore, in the LBC, the causal
association between hepatic fat and fibrosis was
independent of disease activity, suggesting that a
causal effect of long-term liver fat accumulation on
liver disease is independent of inflammation.
Genetically determined hepatic steatosis was asso-
ciated with insulin resistance in the LBC and SOS.
However, this association was dependent on liver
damage severity. Genetically determined hepatic
steatosis was associated with liver fibrosis/cirrho-
sis and with a small increase in risk of type 2
diabetes in publicly available databases.
Conclusion. These data suggest that long-term hepatic
fat accumulation plays a causal role in the devel-
opment of chronic liver disease.
Keywords: fibrosis, genetics, insulin resistance, men-
delian randomization, nonalcoholic fatty liver dis-
ease, type 2 diabetes.
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Introduction
Nonalcoholic fatty liver disease (NAFLD) is defined
by the accumulation of fat in the liver, in the
absence of excessive alcohol consumption. NAFLD
encompasses a spectrum of conditions ranging
from simple accumulation of excess fat (steatosis)
to hepatic inflammation (nonalcoholic steatohep-
atitis or NASH) and fibrosis. Obesity and insulin
resistance are major risk factors for NAFLD [1–3].
Concurrent with the increased prevalence of obe-
sity, NAFLD has emerged as the most frequent liver
disorder worldwide, affecting as many as 30% of
adults in industrialized countries [4, 5].
Although simple steatosis is generally considered
benign, NAFLD is associated with an increased risk
of end-stage liver disease, as well as a range of
extrahepatic metabolic disorders, including insulin
resistance, type 2 diabetes (T2D), dyslipidemia and
hypertension. However, the extent to which these
associations reflect a causal effect of hepatic fat
accumulation remains unclear. Associations
observed in epidemiological studies may be influ-
enced by confounding factors (e.g. diet, physical
activity and microbiota) and/or reverse causation.
Furthermore, hepatic fat accumulation tends to
decrease with the progression of fibrosis (‘burnt-
out nonalcoholic steatohepatitis’) [6], potentially
limiting the ability of cross-sectional association
studies to reliably evaluate the correlates of hepatic
fat in patients with severe disease [7]. Weight-loss
interventions aimed at reducing liver fat lead to
improved metabolic outcomes [8]. However, it is
unclear whether these changes are a direct result
of the reduction in liver fat or a consequence of the
improvement in extrahepatic insulin resistance or
improved lifestyle [3].
Mendelian randomization is an epidemiological
method that avoids confounding and reverse cau-
sation, by using genetic variation as an instrument
to establish the causal role of modifiable risk
factors in disease [9, 10]. The method relies on
the assumption that as an individual’s genotype is
determined randomly at conception, is not related
to lifestyle and other potential confounding factors,
and thus can serve as an unconfounded and
lifelong proxy for an exposure of interest (e.g.
hepatic fat content). As our knowledge of common
genetic variation governing variability in quantita-
tive traits has improved over the past decade as a
result of genomewide association studies (GWAS),
Mendelian randomization has gained widespread
use as a method of testing causal effects of mod-
ifiable risk factors in situations where randomized
controlled trials are not feasible or ethical [11]. For
example, the approach has been used successfully
to assess the causal relationship of different
lipoprotein fractions with the risk of cardiovascular
disease [11]. Previous genomewide association
studies have identified several genetic risk factors
for NAFLD, including variants in PNPLA3 [12, 13],
TM6SF2 [14, 15], GCKR [13], MBOAT7 [16, 17] and
possibly LYPLAL1 [13], which can be used as
instruments to assess the causal effect of hepatic
fat on progressive liver disease. Previous studies
have shown most of these variants to be associated
with NAFLD development and severity [12–14, 17,
18]. However, whether the magnitude of associa-
tion of these genetic variants with progressive liver
disease is concordant with an increase in risk
predicted from their effect on hepatic fat accumu-
lation has not been tested so far. Furthermore,
whether genetically determined hepatic fat influ-
ences insulin resistance remains a controversial
question [3, 19, 20].
Here, we leveraged a Mendelian randomization
approach to examine whether hepatic fat causally
determines liver damage and metabolic comorbidi-
ties. To this end, we evaluated complementary
cohorts of individuals at risk of progressive NAFLD
due to suspected NASH in the Liver Biopsy Cohort
(LBC), or to severe obesity in the Swedish Obese
Subjects Study (SOS), and individuals from the
population-based Dallas Heart Study (DHS). We
sequentially tested whether the steatosis-asso-
ciated variants, individually or combined into a
genetic risk score (GRS), were associated with liver
damage (histological features of NAFLD, amino-
transferases and noninvasive fibrosis scores) and
clinical parameters epidemiologically associated
with insulin resistance and NAFLD (presence of
arterial hypertension, T2D, homoeostasis meta-
bolic assessment-insulin resistance index –
HOMA-IR, and circulating HDL cholesterol).
Materials and methods
Study cohorts
Part of the LBC has been previously described [17,
21]. Briefly, a total of 1515 adult European indi-
viduals who underwent liver biopsy for suspected
NASH or severe obesity were consecutively
enrolled. Individuals with increased alcohol intake
(men, >30 g day1; women, >20 g day1), use of
steatogenic medications or other liver diseases
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were excluded. Demographic and clinical features
of patients included in the LBC were evaluated at
the tertiary referral centres at the time of liver
biopsy. The SOS is a prospective study comparing
the effects of bariatric surgery and usual care in
severely obese individuals in Sweden [22]. A total of
3329 subjects, who had complete baseline meta-
bolic characterization and were successfully geno-
typed, were included. The DHS is a multiethnic
population-based probability sample of Dallas
County residents [23]. The present investigation
included a total of 4570 individuals, who had
provided blood samples for genetic and laboratory
analysis. Of these, 2736 individuals had available
measures of liver fat with proton magnetic reso-
nance spectroscopy (1H-MRS) [1].
All studies were approved by the competent
ethical committees, and all subjects gave written
or oral informed consent. The study cohort char-
acteristics and outcomes are summarized in
Fig. 1, clinical features of individuals evaluated
in the study are presented in Table 1, and
additional details concerning the study design
are provided in Supporting information (Data S1)
and in Figure S1.
Biochemical and clinical end-points
Hypertension was defined as systolic blood pres-
sure ≥140 mm Hg or diastolic blood pressure
≥90 mm Hg, or self-reported antihypertensive
treatment. T2D was defined as fasting blood glu-
cose level ≥126 mg dL1, nonfasting glucose
≥200 mg dL1, HbA1c ≥6.5% or use of glucose-
lowering medication. HOMA-IR was calculated
from fasting levels of glucose and insulin [24].
Plasma levels of lipids and lipoproteins were mea-
sured by standard enzymatic assays. As most of
the risk variants included in the genetic risk score
have been shown to have pleiotropic effects on
circulating cholesterol and triglycerides [18], they
were not regarded as valid instruments for testing
the causal effect of hepatic fat on these outcomes.
Therefore, only HDL levels were considered as an
outcome in this study.
Fig. 1 Study cohorts and outcomes. NASH, nonalcoholic steatohepatitis.
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In the LBC, steatosis, disease activity and fibrosis
were assessed according to the NAFLD clinical
research network criteria [25]. Briefly, steatosis
was scored (on a scale from 0 to 3) according to the
percentage of affected hepatocytes (0: <5%, 1: 5–
33%, 2: 34–66%, 3: 67–100%), and hepatocellular
Table 1 Clinical features of the cohorts of individuals included in the study
Liver biopsy cohort
(N = 1515)
Swedish Obese
Subjects Study
(N = 3329)
Dallas Heart
Study
(N = 4570)
Age, years 43  16 48  6 45  11
Sex, female 722 (48) 2338 (70) 2608 (57)
Ethnicity
European/European descent 1515 (100) NAa 1351 (30)
African American – – 2355 (51)
Hispanic – – 743 (16)
Recruitment
liver disease/morbid obesityb
884 (58)/631 (42) 0/3329 (100) –
ALT, IU L1 42 (23–69) 30 (22–42) 19 (14–27)
AST, IU L1 28 (20–42) 22 (17–28) 21 (17–26)
Statin use, yes 127 (8) – 390 (9)
Hepatic triglyceride content, % – – 3.5 (1.9–7.0)
{N = 2736}
Fatty liver, yesc 1346 (90) – 880 (32)
{N = 2736}
Fibrosis F3-F4, yes 346 (23) – –
BMI, kg m2 32.1 (27–40) 41.0 (38–44) 29.4 (25–34)
Hypertension, yes 459 (36) 2288 (69) 1496 (36)
T2D, yes 400 (26) 501 (15) 561 (12)
Fasting glucose, mg dL1d 95 (86–110) 81 (72–94) 93 (85–102)
{N = 4474}
Fasting insulin, IU mL1 15 (9–21) 17 (12–24) 13 (8–20)
{N = 1082} {N = 4018}
HOMA-IR, U 3.5 (2.2–5.3) 3.5 (2.3–5.5) 3.0 (1.7–5.0)
{N = 1082} {N = 4018}
Total cholesterol, mg dL1e 193  46 220  43 183  40
HDL cholesterol, mg dL1e 46  8 50  11 51  15
{N = 3203}
Triglycerides, mg dL1f 124 (88–177) 159 (115–221) 97 (68–145)
N. of risk alleles 3 (2–4) 2 (1–3) 2 (1–3)
GRS 0.53 (0.47–0.53) 0.43 (0.37–0.48) 0.13 (0.06–0.34)
Values are reported as mean  SD, number (%), or median (IQR), as appropriate. N, number; NA, not assessed; BMI, body
mass index; T2D, type 2 diabetes; HOMA-IR, homoeostasis model assessment-insulin resistance index; HDL, high-density
lipoprotein; ALT, alanine aminotransferases; AST, aspartate aminotransferases; GRS, genetic risk score. Numbers in
curly brackets indicate numbers of individuals with available data for each phenotype. aIn the SOS, information about
ethnicity was not available, but most participants are presumed of European descent; bDefined in the presence of
BMI ≥ 40 kg m2 or ≥35 kg m2 in patients with metabolic comorbidities (type 2 diabetes, dyslipidemia or arterial
hypertension). cIn DHS, NAFLD (steatosis) was defined as hepatic triglyceride content (HTGC) >5.5%. dMultiply by *0.055
e0.026 f0.011 to obtain mmol L1.
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ballooning (0–2) and lobular necroinflammation (0–
3) were also recorded. Fibrosis stage was staged
(from 0, no fibrosis to 4, cirrhosis) to evaluate
disease progression [25]. The scoring of liver biop-
sies was performed by independent pathologists
unaware of the clinical history and genotype of the
patients [21]. The concordance between patholo-
gists within this cohort was very good for fibrosis
and good for steatosis with a coefficient of interob-
server agreement for fibrosis stage and steatosis
grade of 0.89 and 0.76, respectively [26].
In the DHS, we used the APRI score (AST/
platelets 9 100) as a noninvasive marker of fibro-
sis [27], because it showed the strongest associa-
tion with hepatic fat compared to other indices
(Table S1).
Genotyping
To test the causal role of hepatic fat, we selected
genetic variants with validated effects on hepatic
fat accumulation and/or NAFLD severity (in LBC,
DHS and previous GWAS [12–14, 16, 28]) and with
experimental data supporting the causality of the
association, as instruments.
Therefore, the LBC and SOS cohorts were geno-
typed for rs738409 C>G (PNPLA3 I148M),
rs58542926 C>T (TM6SF2 E167K), rs1260326
C>T (GCKR P446L) and rs641738 C>T in the
MBOAT7 locus, as previously described [17, 21].
The genotyping was performed in duplicate by
TaqMan 50-nuclease assays in the LBC and SOS
(Life Technologies, Carlsbad, CA, USA). The dupli-
cate genotype concordance rate was 100%. In the
DHS, genotyping was performed using Illumina
Human Exome BeadChip, as described [12]. A
subset of DHS participants (n = 3300) was previ-
ously genotyped for LYPLAL1 rs12137855 using
TaqMan assays. As the genotypes for this variant
were not available in the LBC and SOS, we did not
include this variant in our primary analysis but
considered it as part of sensitivity analysis (see
Supporting information, Data S2).
Evaluation of associations of NAFLD-associated variants with T2D
and liver-related end-points in GWAS data
We looked up the associations with T2D of the
NAFLD-associated genetic variants in publicly
available databases from T2D GWAS [29, 30]. Data
were downloaded from the Diagram Consortium at
http://diagram-consortium.org/downloads.html,
and in the case of TM6SF2 rs58542926 (E167K),
extracted directly from Fuchsberger et al. [30]. As
GCKR rs1260326 (P446L) has likely pleiotropic
effects on glucose metabolism, we reported the
effect but did not consider it as a proxy for hepatic
fat when evaluating T2D risk in a Mendelian
randomization context.
Two-sample Mendelian randomization analysis
was performed using the ‘MendelianRandomiza-
tion’ package in R. The per-allele associations of
the PNPLA3, TM6SF2 and MBOAT7 variants with
hepatic fat content in the DHS were entered as
exposures, and the GWAS associations with T2D
were used as outcomes. A summary estimate was
calculated using the inverse variance weighted
method. As described above, GCKR rs1260326
(P446L) was not included in this analysis due to
the strong pleiotropic effects of this SNP on plasma
glucose levels.
Associations with ICD-code defined liver end-points
were extracted from http://geneatlas.roslin.ed.ac.
uk/, a publically available database of genetic
associations in the UK Biobank (n = 408 455). Beta
coefficients and P-values were extracted for associ-
ations with ICD-10 K76 (‘other diseases of liver’)
and K74 (‘fibrosis and cirrhosis of liver’).
Statistical analysis
We used four established risk variants for hepatic
fat accumulation [17, 31] as instruments in Men-
delian randomization analysis. To increase power,
we also created a genetic risk score (GRS) for
hepatic fat accumulation composed of these vari-
ants. The association of each genetic variant with
hepatic steatosis was estimated using linear
regression models in all individuals with available
measures of hepatic steatosis (1515 in LBC and
2736 in DHS). GRS was then calculated across all
three cohorts by summing the number of steatosis
predisposing alleles, weighted by their effect size
(beta coefficient) on steatosis. Weights derived from
severely obese individuals in the LBC were used to
calculate the GRS in the SOS cohort, due to similar
ethnic and clinical make-up of the participants.
The GRS was strongly correlated with steatosis,
explaining 7.0% and 3.5% of its variability in the
LBC and DHS, respectively (Table S2). As steatosis
was graded on an ordinal categorical scale in the
LBC, we also performed a sensitivity analysis,
using ordinal regression models to assess the
relationship of genetic variants with steatosis
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grade. GRS constructed based on ordinal regres-
sion models had very similar associations with liver
damage and metabolic outcomes. Therefore, we
decided to use the GRS estimated from linear
regression models (in both cohorts) for our primary
analyses.
Observational associations of hepatic steatosis
with NAFLD and NAFLD-associated metabolic
traits were assessed using linear and logistic
regression models, with steatosis grade (LBC) or
hepatic fat content (DHS) as an explanatory vari-
able, and each trait as the outcome. The causal
effect of hepatic steatosis on NAFLD and metabolic
traits was estimated using the Wald (ratio) method,
with standard errors approximated by the delta
method [32]. All models were adjusted for age, sex,
recruitment centre (in the LBC), ethnicity (in DHS),
body mass index (BMI) and statin use. All esti-
mates are standardized. The reported observa-
tional estimates are for a 1-SD unit increase in
hepatic fat. The causal estimates are for a 1-SD
unit increase in genetically determined hepatic fat
content. We conducted sensitivity analyses, using
alternative GRS, calculated by excluding one
genetic variant at a time, and using an unweighted
risk score.
Statistical analyses were carried out using R sta-
tistical analysis software version 3.3.2 (http://
www.R-project.org/). P-values < 0.05 were consid-
ered statistically significant.
Results
Observational association of hepatic fat with liver damage and
metabolic traits
In the observational analysis, hepatic fat content
was strongly associated with aminotransferases
(P < 1016, Table 2), in two of the study cohorts
with available measures of hepatic fat (LBC and
DHS). Further, it was associated with histological
necroinflammation (P < 10115), ballooning (P <
1048) and fibrosis stage (P < 1050) in the LBC,
and with the APRI fibrosis score in the DHS
(P = 9.8 9 105). In both cohorts, hepatic fat was
also associated with the prevalence of hyperten-
sion, T2D, increased insulin resistance (HOMA-IR)
and with lower HDL (all P < 0.05).
Association of genetic variants with hepatic fat, liver damage and
metabolic traits
The frequency distribution of the number of risk
alleles carried by each individual in the three
Table 2 Observational association of study outcomes with histological steatosis severity in the liver biopsy cohort (LBC;
n = 1515 at risk of NASH) and hepatic TG content in the Dallas Heart Study (DHS; n = 2736 from the general population)
Liver biopsy cohort (N = 1515) Dallas Heart Study (N = 2736)
b 95% c.i. P value b 95% c.i. P value
ALT, IU L1 +0.34 (0.30–0.38) 9.0 9 1054 +0.25 (0.22–0.29) 2.0 9 1040
AST, IU L1 +0.29 (0.25–0.34) 4.0 9 1035 +0.17 (0.13–0.21) 6.6 9 1017
Necroinflammation +0.53 (0.49–0.58) 5.0 9 10115 – – –
Ballooning +0.33 (0.29–0.38) 7.1 9 1049 – – –
Fibrosis stage +0.35 (0.30–0.39) 2.1 9 1051 – – –
APRI scorea – – – +0.09 (0.04–0.13) 9.8 9 105
Hypertension, yes +0.13 (0.07–0.18) 1.0 9 105 +0.17 (0.06–0.27) 0.0018
T2D, yes +0.12 (0.08–0.17) 5.8 9 107 +0.45 (0.30–0.59) 2.6 9 109
HOMA-IR +0.25 (0.20–0.31) 1.5 9 1022 +0.29 (0.26–0.33) 1.3 9 1060
HDL 0.06 (0.11 to 0.01) 0.011 0.15 (0.19 to 0.12) 5.5 9 1015
Adjusted standardized beta coefficients and (95% c.i.) are reported. Coefficients were adjusted for age, sex, BMI, use of
statins, recruitment centre in the LBC or ethnicity in the DHS. The regression coefficients are expressed in unit of SD of
feature per unit increment in histological steatosis grade (which was approximated to a continuous trait and normalized)
in the LBC or a 1 SD change in hepatic triglyceride content in the DHS. For binary outcomes, the relationship was
assessed using logistic regression, with beta coefficients representing the log of the odds of the outcome per a one-unit
increment in steatosis grade or a 1 SD change in hepatic fat content. BMI, body mass index; T2D, type 2 diabetes; HOMA-
IR, homoeostasis model assessment-insulin resistance index; HDL, high-density lipoprotein cholesterol; ALT, alanine
aminotransferases; AST, aspartate aminotransferases. After correction for multiple comparisons, P < 0.0065 and
P < 0.0071 are considered statistically significant in the LBC and DHS, respectively. aAvailable for N = 1933 in DHS.
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cohorts is shown in Figure S2. The impact of the
individual risk variants on hepatic fat, liver dam-
age and metabolic traits is presented in Table S3.
As previously reported, in the LBC and DHS,
PNPLA3 rs738409 (I148M) was the strongest
genetic determinant of hepatic fat, followed by
TM6SF2 rs58542926 (E167K), while GCKR
rs1260326 (P446L) and MBOAT7 rs641738 had
smaller but significant effects. Of the four individ-
ual variants, PNPLA3 rs738409 (I148M) was also
associated with higher liver enzymes in all three
cohorts. All four gene variants were associated with
the full spectrum of liver damage, related to
NAFLD, in the LBC.
The impact of genetic risk variants on liver damage
was proportional to their effect on hepatic fat
accumulation (Fig. 2), consistent with the notion
that their impact on liver damage is mainly medi-
ated by increased liver fat and not by other
pleiotropic effects. In a sensitivity analysis using
ordinal regression models, we confirmed a close
correlation between the impact of genetic variants
on steatosis and that on fibrosis in the LBC
(Figure S3).
The PNPLA3 rs738409 (I148M) variant was associ-
ated with increased HOMA-IR in the LBC and SOS
cohorts but not in the DHS (Table S3).
Causal effect of hepatic fat on liver damage and metabolic traits
The estimated causal effects of hepatic fat on histo-
logical and metabolic traits associated with NAFLD
are shown in Table 3 and in Fig. 3. The GRS was not
associated with age, sex and anthropometric traits
(not shown). A genetically determined increase in
hepatic fatwas associatedwith elevated aminotrans-
ferases in all three cohorts (P < 109 in the LBC,
P < 1014 in the SOS and P < 103 in the DHS) and
with histological features of NAFLD-related liver
damage in the LBC, including necroinflammation
and ballooning (P < 1016 and P < 109, respec-
tively), as well as fibrosis stage (P < 1012). Of note,
in the LBC, genetically predicted steatosis had a
larger impact on fibrosis than the observed histolog-
icalsteatosis.Finally, thecausalassociationbetween
hepatic fat and fibrosis was independent of necroin-
flammation and hepatocellular ballooning
(b = +0.37, 95% c.i. 0.21–052; P = 5.2 9 106). In
a sensitivity analysis that used two-stage least
Fig. 2 Comparison of the
impact of risk variants: PNPLA3
I148M (rs738409), TM6SF2
E167K (rs58542926), GCKR
P446L (rs1260326) and
MBOAT7 rs641738 on hepatic
fat vs. liver damage. Panel a:
histological steatosis vs.
ballooning in the LBC
(R2 = 0.70). b: histological
steatosis vs.
necroinflammation in the LBC
(R2 = 0.76). c: histological
steatosis vs. fibrosis in the LBC
(R2 = 0.97). d: hepatic fat
content vs. serum ALT levels in
the DHS (R2 = 1). Beta
coefficients and 95%
confidence intervals are shown
for each variant. [Correction
added on 18 January 2018
after first online publication: In
Figure 2B and D, the color
labels for PNPLA3 and TM6SF2
have been interchanged for
clarity]
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squares regression (rather than the ratio method) to
calculate causal estimates, the results did not
change substantially (Data S1 and Table S4), except
that genetically determined hepatic fat was addition-
allyassociatedwithfibrosis (asestimatedbytheAPRI
score) in the DHS (P < 0.05). These results suggest
that hepatic fat accumulation causally promotes the
full spectrumof liverdamageassociatedwithNAFLD.
In the LBC, genetically determined hepatic fat was
associated with HOMA-IR, to an extent similar to
that of observed steatosis, suggesting that hepatic
fat causes insulin resistance, consistent with the
reported epidemiological association (Table 3 and
Fig. 3). The effect of steatosis on HOMA-IR became
more marked after excluding patients with T2D
(b = +0.41, 95% c.i. 0.15–0.64; P = 0.00078), but it
was attenuated after correction for fibrosis
(b = +0.10, 95% c.i. 0.10–0.33; P = 0.26). Simi-
larly, in the SOS, genetically determined hepatic fat
was causally associated with HOMA-IR (b = +0.21;
95% c.i. 0.06–0.35; Table 3 and Fig. 3), but the
association was lost after correction for serum ALT,
used as a measure of liver damage (b = +0.10; 95%
c.i. 0.05–0.24; P = 0.20). We did not detect a
significant effect of genetically determined hepatic
fat on insulin resistance in the population-based
DHS (Table 3).
To validate the causal association between hep-
atic fat and insulin resistance, we extracted
results from the largest publicly available GWAS
on T2D (Table 4). The risk alleles of the two
strongest steatogenic variants, PNPLA3 rs738409
(I148M) and TM6SF2 rs58542926 (E167K), were
associated with a small increase in the risk of
T2D (allelic ORs 1.04, 95% c.i. 1.01–1.07 and
1.14, 95% c.i. 1.10–1.19, respectively). The asso-
ciation of the MBOAT7 variant was directionally
concordant but not significant (OR 1.02, 95% c.i.
0.99–1.05; P = 0.19). The major (P) allele of GCKR
rs1260326 P446L (which reduces the risk of
NAFLD) was associated with a modestly increased
risk of T2D (OR 1.06, 95% c.i. 1.03–1.09).
However, GCKR rs1260326 P446L is known to
associate strongly with plasma glucose levels, a
pleiotropic association that makes it problematic
to use this variant as a proxy for hepatic fat in a
Mendelian randomization context with T2D as an
outcome.
In two-sample Mendelian randomization analysis
using the PNPLA3, TM6SF2 and MBOAT7 variants
as instruments for hepatic fat, the causal OR for
risk of T2D for a 1 standardized unit increase in
genetically determined hepatic fat was 1.31 (95%
c.i., 1.20–1.43; P = 1.2 x 109).
Fig. 3 Comparison of the epidemiological association of observed hepatic fat with NAFLD features (open circles) with the
causal association of hepatic fat with NAFLD-related features (filled circles) in the LBC (n = 1515, panel a), the SOS
(n = 3329, panel b) and the DHS (n = 2736, panel c). T2D, type 2 diabetes; HOMA-IR, homoeostasis model assessment-
insulin resistance index; HDL, high-density lipoprotein; ALT, alanine aminotransferases; AST, aspartate aminotrans-
ferases. Results were adjusted for age, sex, BMI, modality of recruitment in the LBC and ethnicity in the DHS, use of statins
and (for the metabolic parameters) the severity of liver fibrosis. Estimates are beta coefficients, and error bars are 95%
confidence intervals.
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Sensitivity analyses
To rule out the possibility that the association of
the GRS with NAFLD-associated traits was biased
by the specific mechanism of action of single
genetic risk variants, we conducted sensitivity
analyses using alternative GRS, calculated by
excluding a single risk variant at a time
(Table S2). The results evaluating the association
of alternative GRS with NAFLD features are shown
in Table S5.
All GRS were associated with hepatic fat, although,
as expected, those excluding PNPLA3 rs738409
(I148M) were less robustly associated than the
other scores, across all cohorts. The associations
between alternative GRS and NAFLD-associated
traits were generally consistent with those for the
full score, based on four variants. Importantly,
most alternative models confirmed a causal asso-
ciation of hepatic fat with liver enzymes and
histological liver damage. The only exception was
that the associations with aminotransferases in the
DHS were no longer statistically significant when
excluding the PNPLA3 variant, likely due to the
lack of power (Table S5). In the LBC, we also
confirmed a trend for association of the alternative
GRS with increased insulin resistance.
To confirm the association of the steatogenic vari-
ants with liver disease in a separate cohort, we
performed a lookup in a publically available
database of genetic associations in 408 455 partic-
ipants from UK Biobank (as reported in the
Methods and in Supporting information, Data S1).
The steatogenic alleles in PNPLA3, TM6SF2, GCKR
and MBOAT7 all associated with increased risk of
ICD-defined ‘other diseases of liver’ (K76), which
includes NAFLD (n = 408 455, P = 0.0075–
2 9 1012, Table S6 and Figure S4). Variants in
PNPLA3, TM6SF2 and MBOAT7 associated with
increased risk of ‘fibrosis and cirrhosis of liver’
(K74; P = 0.002–3 9 106, Table S6). In two-sam-
ple Mendelian randomization analysis, a standard-
ized 1-unit increase in genetically determined
hepatic fat content was associated with an
increased risk of ‘other diseases of liver’
(P = 5 9 1019), and with ‘fibrosis and cirrhosis of
liver’ (P = 9 9 1011).
Additional sensitivity analyses, evaluating an alter-
native GRS including the LYPLAL1 rs12137855
variant, using beta coefficients derived from
external cohorts, and showing the results in
patients stratified according to modality of recruit-
ment and ethnicity are reported in Supporting
information.
Discussion
The current study represents the first attempt to
apply a formal Mendelian randomization frame-
work to test whether hepatic fat is causally related
to liver damage and fibrosis. The main findings of
this work are as follows: (i) the magnitude of
association of genetic risk variants with fibrosis
severity, the major prognostic determinant in
NAFLD, is proportional to their effect on steatosis,
suggesting that the association between these
genetic variants and liver disease is explained by
hepatic fat accumulation; (ii) the association
between hepatic fat accumulation and fibrosis
was independent of inflammation, suggesting that
it is not influenced by pleiotropic effects of genetic
variants on inflammation; (iii) the effect size of
genetically predicted steatosis on fibrosis was
Table 4 Association of NAFLD-variants with type 2 diabetes in published GWAS
Gene SNP Effect allele
other
allele T2D OR 95% c.i. P value N Data source
PNPLA3 rs738409 G (minor) C 1.04 1.01–1.07 0.0045 100 323 diagram.mega-meta
TM6SF2 rs58542926 T (minor) C 1.14 1.10–1.19 3.2 9 1010 92 794 Fuchsberger 2016 [30]
MBOAT7 rs641738 T (minor) C 1.02 0.99–1.05 0.19 76 306 diagram.mega-meta
GCKR rs1260326 C (major)a T 1.06 1.03–1.09 3.4 9 105 100 584 diagram.mega-meta
Data were downloaded from http://diagram-consortium.org/downloads.html or extracted from Fuchsberger et al. [30].
aThe effect allele in GCKR is the major allele, encoding GCKR 446P. The 446P-allele causes a relative gain-of-function
compared to the L-allele, leading to less hepatic phosphorylation of glucose, increased blood glucose and thus an
increased risk of type 2 diabetes (T2D). Due to these strong pleiotropic effects of GCKR on glucose metabolism, it is
problematic to use this variant as a proxy for NAFLD in Mendelian randomization analyses with T2D as an outcome.
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consistent with that of observational steatosis,
suggesting that long-term exposure to steatosis
causes fibrosis independently of confounders; (iv)
the association of genetically determined hepatic
fat with insulin resistance was restricted to high-
risk individuals, suggesting that insulin resistance
is not a direct consequence of hepatic fat accumu-
lation but a phenomenon possibly mediated by
liver damage. A schematic representation of these
study findings is presented in Fig. 4.
Although the associations of the four gene variants
included in our risk score with NAFLD progression
have been previously reported [17, 18], whether
these effects are consistent with a causal role of
hepatic fat or are explained by other pleiotropic
effects of the genetic variants has not been exam-
ined so far. Here, we observed a clear dose–
response relationship between the genetic effects
on hepatic fat content and liver damage, in partic-
ular the severity of fibrosis, the major prognostic
determinant in patients with NAFLD [33]. Further-
more, genetically determined liver fat was strongly
associated with liver fibrosis and cirrhosis in the
UK Biobank database. These data suggest that the
impact of these variants on liver damage predispo-
sition is mainly determined by hepatic fat accu-
mulation.
To increase statistical power, we constructed a
GRS from the four risk variants. The GRS was
strongly associated with hepatic fat content and
with aminotransferase levels, as well as with the
entire spectrum of histological liver damage. Inter-
estingly, the estimated causal effect of hepatic
steatosis was larger than the observational associ-
ation of histological steatosis with fibrosis. This
likely reflects the lifelong exposure to steatosis in
carriers of steatogenic variants [11] and suggests
that the histological grade of steatosis at the time of
biopsy may underestimate the full impact of hep-
atic fat accumulation on fibrosis. In addition, the
causal effect of hepatic fat on fibrosis was partly
independent of disease activity at the time of
biopsy, supporting the active role of hepatic fat
accumulation in inducing progressive liver disease
over the entire lifetime. These data are consistent
with experimental evidence linking hepatic fat
accumulation and insulin resistance with fibrosis
in NAFLD, independent of inflammatory pathways
[34].
Hepatic steatosis has been hypothesized to repre-
sent an ‘innocent bystander’ in the pathogenesis of
NASH, or even a protective response to increased
free fatty acids availability [35]. In contrast to these
hypotheses, rare mutations predisposing to severe
hepatic fat accumulation frequently lead to cirrho-
sis and hepatocellular carcinoma even in the
absence of other hepatotoxic insults [36]. Further-
more, a recent population-based twin study
found that liver steatosis and fibrosis tend to be
Fig. 4 Schematic
representation of main study
findings. Hepatic fat
accumulation is causally
associated with increased liver
enzymes, hepatocellular
damage, necroinflammation
and fibrosis. TAG, triglycerides,
AST, aspartate
aminotransferases, ALT,
alanine aminotransferases,
HSCs, hepatic stellate cells.
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co-inherited [37]. The present results suggest that
hepatic steatosis promotes the full spectrum of
liver disease. Potential mechanisms include
reduced ability to incorporate fatty acids in lipid
droplets under stress conditions, spillover or
peroxidation of fatty acids and activation of lipid-
droplet dependent signalling pathways [38]. How-
ever, these results do not necessarily imply that
triglyceride accumulation are the driver of liver
disease progression, because NAFLD risk variant
are associated with hepatic accumulation of differ-
ent lipid species [39]. Therefore, experimental
studies are still required to investigate the mech-
anism underlying this association.
Finally, we found that hepatic steatosis is causally
associated with insulin resistance in individuals at
risk of NASH because of severe liver disease or
obesity, in a liver damage dependent fashion. The
association between genetically determined hep-
atic fat and insulin resistance was not observed in
the DHS, possibly due to the low prevalence of
individuals with advanced liver fibrosis in this
general population. Alternatively, the lack of asso-
ciation may be a result of reduced power, owing to
the fact that the impact of the genetic risk variants
for NAFLD on liver damage was more marked in
individuals with acquired risk factors such as
obesity [40]. The steatogenic variants were associ-
ated with an increased T2D risk in the largest T2D
GWAS [30] and in a recently published study
including >300 000 individuals with metabolic
characterization [41]. In our study, the association
between a genetically increased liver fat content
and insulin resistance appeared to depend on the
presence of liver damage. This might reflect
decreased hepatic insulin signalling induced by
accumulation of specific lipid species or a fibrosis-
mediated decrease in hepatic insulin clearance [42,
43]. Taken together, these data support the
hypothesis that inhibition of hepatic fat accumu-
lation might lead to improvement of insulin resis-
tance and a reduction in risk of T2D, secondary to
the improvement of liver disease.
There are limitations to our study. We evaluated a
small number of variants, but given the high
heritability of NAFLD [31], the GRS explained a
larger fraction of phenotypic variability than most
scores based on a large number of variants in
similar studies conducted for other complex traits
[32]. An underlying assumption of the Mendelian
randomization method is that genetic variants
used as proxies for exposure influence the outcome
solely via their effect on the exposure and not via
pleiotropic effects. TM6SF2 rs58542926 (E167K)
impairs hepatic secretion of lipoproteins and
reduces plasma levels of triglycerides and choles-
terol. However, reduced levels of lipoproteins are
not likely to directly cause liver damage. GCKR
rs1260326 (P446L) increases the trapping of glu-
cose in the liver and has an impact on plasma
levels of glucose and insulin. This may pose a
problem when using the variant as a proxy for
hepatic fat with T2D as an outcome. MBOAT7
rs641738 is associated with changes in circulating
levels of phosphatidylinositols [17], which are
unlikely to influence liver damage. Even though
we cannot rule out a possibility that PNPLA3
rs738409 (I148M) also promotes liver damage by
alternate mechanisms, for example by altering
retinol metabolism [44], our results held consistent
when excluding the PNPLA3 rs738409 (I148M)
from the GRS. In summary, pleiotropic effects are
unlikely to explain the main findings of our study,
even if pleiotropy remains an unavoidable limita-
tion of the Mendelian randomization approach [11,
45].
To reduce bias, we performed several sensitivity
analyses, including the evaluation of alternative
GRS, and validated the results in three indepen-
dent cohorts. Steatosis grade (a categorical pheno-
type) was approximated to a continuous trait in the
LBC. However, using steatosis grade as an ordinal
categorical trait did not change the results. Finally,
direct measurement of hepatic fat content was not
available in the SOS, and causes of fatty liver other
than NAFLD could not be ruled out in the DHS and
SOS.
Conclusion
Genetic variants that increase hepatic fat content
are associated with an increase in biochemical
markers of liver damage and the risk of hepatic
fibrosis, to the degree predicted by their steato-
genic effects. This supports the hypothesis that
hepatic steatosis per se is likely to be a causal risk
factor for the development of liver fibrosis, inde-
pendent of inflammation. In addition, genetic vari-
ants that increase hepatic fat content were
associated with modest increases in insulin resis-
tance and risk of T2D. However, these associations
were only observed in individuals with liver dis-
ease, suggesting that liver disease, rather than
hepatic steatosis, could be the underlying causal
factor. Taken together, these data suggest that
Hepatic fat accumulation causes liver disease / P. Dongiovanni et al.
ª 2017 The Authors Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine 367
Journal of Internal Medicine, 2018, 283; 356–370
interventions aimed at reducing hepatic steatosis
are likely to have long-term beneficial effects on
liver disease and potentially on insulin resistance
in patients with NAFLD.
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Table S1. Noninvasive fibrosis scores tested in the
DHS for association with hepatic fat content.
Table S2. Coefficient used to develop genetic risk
scores (GRS) applied in the study cohorts (full
models and sensitivity analysis conducted by
removing one genetic variant at time).
Table S3. Association of genetic variants included
in the GRS (PNPLA3 rs738409 I148M, TM6SF2
rs58542926 E167K, GCKR rs1260326 P446L, and
MBOAT7 rs641738) with liver damage and clinical
parameters epidemiologically associated with
NAFLD, in the LBC (N = 1515), SOS (N = 3329),
and DHS (N = 4570). Estimates of b variant-feature are
reported for adjusted models.
Table S4. Causal effect estimates of hepatic fat
content, as evaluated by instrumental regression
analysis by the 2SLS method, on metabolic and
hepatic correlates of NAFLD in the LBC (n = 1515
at risk of NASH) and the DHS (n = 2736 from the
general population).
Table S5. Sensitivity analyses of IV regression
analysis evaluating the causal role of hepatic fat on
the hepatic and metabolic NAFLD features in the
study cohorts with alternative GRS excluding one
genetic risk variant per time. Estimate of causality
- b coefficient - (95% confidence intervals) and P
values are reported for adjusted models.
Table S6. Associations of steatogenic variants with
ICD-code defined liver endpoints in 408 455 par-
ticipants from UKBiobank.
Table S7. Weights used in GRS construction in
DHS.
Table S8. Impact of the LYPLAL1 rs12137855
variant on hepatic and metabolic features of
NAFLD in the DHS. Estimate of bvariant-feature are
reported for adjusted models.
Table S9. Association of genetically determined
hepatic fat with liver damage and metabolic fea-
tures, using alternative GRS-S1 and GRS-S2.
Table S10. Sensitivity analysis: causal effect esti-
mates of hepatic fat content on hepatic and
metabolic correlates of NAFLD in the LBC, strati-
fied by modality of recruitment (Hepatology clinics
vs. Bariatric surgery centers) in the LBC.
Table S11. Causal effect estimates of hepatic fat
content on hepatic and metabolic correlates of
NAFLD in the DHS, stratified by ethnicity.
Figure S1. Schematic representation of the princi-
ples of Mendelian randomization.
Figure S2. Frequency distribution of the number of
risk variants for hepatic fat accumulation in
PNPLA3, TM6SF2, GCKR, and MBOAT7 carried by
each individual in the LBC, SOS, and in the DHS.
Figure S3. Comparison of the impact of the eval-
uated common risk variants in PNPLA3, TM6SF2,
GCKR, and MBOAT7 on steatosis grade vs. fibrosis
stage in the LBC by ordinal regression analysis.
Figure S4. Comparison of the impact of the eval-
uated common risk variants in PNPLA3, TM6SF2,
GCKR, and MBOAT7 on hepatic fat content vs.
other liver diseases (ICD9-K76, including NAFLD)
in the UKBiobank (n = 408 455). Beta coefficients
and 95% confidence intervals are shown.
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